© The Author 2006. Published by Oxford University Press.
ARTICLE |
Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention
For the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Affiliations of authors: Institut d'Investigació Biomèdica de Bellvitge, Cancer Epidemiology and Registration Unit, Institut Català d'Oncologia. L'Hospitalet de Llobregat, Barcelona, Spain (XC, MD, SdS, NM, FXB); Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, San José, Costa Rica (RH); International Agency for Research on Cancer, Lyons, France (SF); National Laboratory for Sexually Transmitted Diseases, Health Canada, Winnipeg, Manitoba, Canada (RWP); University of Washington, Seattle, WA (RA); University of North Carolina, Chapel Hill, NC (JSS); Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands (PJFS, CJLMM)
Correspondence to: Xavier Castellsagué, MD, MPH, PhD, Servei d'Epidemiologia i Registre del Càncer, Institut Català d'Oncologia, Gran via s/n, km 2.7, E-08907 L'Hospitalet de Llobregat, Barcelona, Spain (e-mail: xcastellsague{at}ico.scs.es).
Background: Most cancers of the uterine cervix are squamous cell carcinomas. Although the incidence of such carcinomas of the uterine cervix has declined over time, that of cervical adenocarcinoma has risen in recent years. The extent to which human papillomavirus (HPV) infection and cofactors may explain this differential trend is unclear. Methods: We pooled data from eight case–control studies of cervical cancer that were conducted on three continents. A total of 167 case patients with invasive cervical adenocarcinoma (112 with adenocarcinoma and 55 with adenosquamous carcinoma) and 1881 hospital-based control subjects were included. HPV DNA was analyzed in cervical specimens with the GP5+/6+ general primer system followed by type-specific hybridization for 33 HPV genotypes. Blood samples were analyzed for chlamydial and herpes simplex virus 2 (HSV-2) serology. Multivariable unconditional logistic regression modeling was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs). All tests of statistical significance were two-sided. Results: The adjusted overall odds ratio for cervical adenocarcinoma in HPV-positive women compared with HPV-negative women was 81.3 (95% CI = 42.0 to 157.1). HPV 16 and HPV 18 were the two most commonly detected HPV types in case patients and control subjects. These two types were present in 82% of the patients. Cofactors that showed clear statistically significant positive associations with cervical adenocarcinoma overall and among HPV-positive women included never schooling, poor hygiene, sexual behavior–related variables, long-term use of hormonal contraception, high parity, and HSV-2 seropositivity. Parity had a weaker association with adenocarcinoma and only among HPV-positive women. Use of an intrauterine device (IUD) had a statistically significant inverse association with risk of adenocarcinoma (for ever use of an IUD compared with never use, OR = .41 [95% CI = 0.18 to 0.93]). Smoking and chlamydial seropositivity were not associated with disease. Conclusions: HPV appears to be the key risk factor for cervical adenocarcinoma. HPV testing in primary screening using current mixtures of HPV types and HPV vaccination against main HPV types should reduce the incidence of this cancer worldwide.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Etiology and Prevention of Cervical Adenocarcinomas
- Allan Hildesheim and Amy Berrington de González
J Natl Cancer Inst 2006 98: 292-293.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  A. K. Chaturvedi, R. A. Kleinerman, A. Hildesheim, E. S. Gilbert, H. Storm, C. F. Lynch, P. Hall, F. Langmark, E. Pukkala, M. Kaijser, et al. Reply to P.A. Leppaluoto J. Clin. Oncol., June 20, 2009; 27(18): 3066 - 3067. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lazarczyk, P. Cassonnet, C. Pons, Y. Jacob, and M. Favre The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections Microbiol. Mol. Biol. Rev., June 1, 2009; 73(2): 348 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schenk, T. Brandstetter, A. zur Hausen, J. Alt-Morbe, D. Huzly, and J. Ruhe Performance of a Polymer-Based DNA Chip Platform in Detection and Genotyping of Human Papillomavirus in Clinical Samples J. Clin. Microbiol., May 1, 2009; 47(5): 1428 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Reimers, W. F. Anderson, P. S. Rosenberg, D. E. Henson, and P. E. Castle Etiologic Heterogeneity for Cervical Carcinoma by Histopathologic Type, Using Comparative Age-Period-Cohort Models Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 792 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Chaturvedi, R. A. Kleinerman, A. Hildesheim, E. S. Gilbert, H. Storm, C. F. Lynch, P. Hall, F. Langmark, E. Pukkala, M. Kaijser, et al. Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix J. Clin. Oncol., February 20, 2009; 27(6): 967 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lazcano-Ponce, L. S. Palacio-Mejia, B. Allen-Leigh, E. Yunes-Diaz, P. Alonso, R. Schiavon, and M. Hernandez-Avila Decreasing Cervical Cancer Mortality in Mexico: Effect of Papanicolaou Coverage, Birthrate, and the Importance of Diagnostic Validity of Cytology Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2808 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Monsonego, G. Pollini, M. J. Evrard, P. Sednaoui, L. Monfort, D. Quinzat, R. Dachez, and K. Syrjanen Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear Int J STD AIDS, June 1, 2008; 19(6): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steben Do you approve of spending $300 million on HPV vaccination?: YES Can Fam Physician, February 1, 2008; 54(2): 174 - 176. [Full Text] [PDF]
|
|
|
|
|
|
M. Steben Approuvez-vous les 300 M $ pour la vaccination contre le VPH?: OUI Can Fam Physician, February 1, 2008; 54(2): 178 - 180. [Full Text] [PDF]
|
|
|
|
|
|
Y P Bao, N Li, J S Smith, and Y L Qiao Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis Int J STD AIDS, February 1, 2008; 19(2): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Outterson and A. S. Kesselheim Market-Based Licensing For HPV Vaccines In Developing Countries Health Aff., January 1, 2008; 27(1): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Strander, A. Andersson-Ellstrom, I. Milsom, and P. Sparen Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study BMJ, November 24, 2007; 335(7629): 1077 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Garland, M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. M. Harper, S. Leodolter, G. W.K. Tang, D. G. Ferris, M. Steben, J. Bryan, et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases N. Engl. J. Med., May 10, 2007; 356(19): 1928 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 As with Squamous Tumors, HPV Is Key in Cervical Adenocarcinoma Etiology Journal Watch Women's Health, May 2, 2006; 2006(502): 4 - 4. [Full Text]
|
|
|
|
 |
|
 A. Hildesheim and A. B. de Gonzalez Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst, March 1, 2006; 98(5): 292 - 293. [Full Text] [PDF]
|
|